Larkberget

Larkberget Liabilities

The The Liabilities of Larkberget (LARK.ST) as of Nov 15, 2026 is 1.24 M SEK. In the previous year, The Liabilities was 4.30 M SEK — a change of -71.19% (lower).

Liabilities

1.24 MSEK

YoY

-71.19%

Last updated:

In 2025, Larkberget's total liabilities amounted to 1.24 M SEK, a -71.19% difference from the 4.30 M SEK total liabilities in the previous year.

The Larkberget Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
14.66 M SEK
Jan 1, 2019
23.51 M SEK
Jan 1, 2020
7.98 M SEK
Jan 1, 2021
7.94 M SEK
Jan 1, 2022
6.10 M SEK
Jan 1, 2023
4.16 M SEK
Jan 1, 2024
4.30 M SEK
Jan 1, 2025
1.24 M SEK
The Larkberget Liabilities history
YEARLiabilitiesYoY
1.24 MSEK-71.19%
4.30 MSEK+3.47%
4.16 MSEK-31.86%
6.10 MSEK-23.21%
7.94 MSEK-0.49%
7.98 MSEK-66.06%
23.51 MSEK+60.38%
14.66 MSEK+801.06%
1.63 MSEK+100.96%
809,661.00SEK+17.05%
691,731.00SEK+18.85%
582,043.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Larkberget Stock analysis

What does Larkberget do? CombiGene AB specializes in developing treatments for neurological disorders using gene therapy vectors. The company's platform delivers combinations of transgenes encoding neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors. CombiGene focuses on an epilepsy treatment utilizing an adeno-associated virus (AAV) vector carrying transgenes for NPY and its Y2 receptor. The firm targets neurological and psychiatric diseases in humans and animals through its gene therapy approach. CombiGene AB's products are developed for the treatment of epilepsy and other neurological conditions. The company's platform is designed to deliver multiple therapeutic elements simultaneously via gene therapy vectors. The firm's focus on AAV vectors carrying specific transgenes reflects its strategy to address complex neurological disorders with targeted gene-based therapies. The company's target segments include patients with neurological and psychiatric diseases requiring innovative treatment options. CombiGene AB's development pipeline centers on epilepsy treatment using NPY and Y2 receptor transgenes. The firm's approach involves creating therapies that combine multiple biological components to address disease mechanisms more effectively. Larkberget is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Larkberget's Liabilities

Larkberget's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Larkberget's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Larkberget's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Larkberget's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Larkberget’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Larkberget stock

The Liabilities of Larkberget is 1.24 M SEK in 2025.

The Liabilities of Larkberget changed from 4.30 M SEK to 1.24 M SEK, representing a -71.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Larkberget since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Larkberget historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Larkberget

All Key Metrics — Larkberget